BetterLife Pharma Inc.
BETR
CNSX
| 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -33.94% | -47.49% | -39.54% | -79.73% | 4.81% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -27.58% | -46.39% | -54.10% | -80.18% | -17.75% |
| Operating Income | 27.58% | 46.39% | 54.10% | 80.18% | 17.75% |
| Income Before Tax | 47.89% | -164.32% | 65.31% | 90.35% | -5.08% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 47.89% | -164.32% | 65.31% | 90.35% | -5.08% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -96.38% | 126.58% | 9.38% | -104.11% | 104.90% |
| Net Income | 45.80% | -166.91% | 65.76% | 89.63% | 46.34% |
| EBIT | 27.58% | 46.39% | 54.10% | 80.18% | 17.75% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 52.50% | -155.88% | 72.41% | 91.13% | 52.38% |
| Normalized Basic EPS | 65.71% | -1,300.00% | 72.22% | 86.96% | 61.11% |
| EPS Diluted | 67.80% | -164.71% | 72.73% | 89.47% | 29.76% |
| Normalized Diluted EPS | 65.71% | -1,300.00% | 72.22% | 86.96% | 61.11% |
| Average Basic Shares Outstanding | 16.95% | 17.30% | 24.29% | 12.26% | 12.73% |
| Average Diluted Shares Outstanding | 16.95% | 3.48% | 24.29% | 12.26% | 12.73% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |